Vaccinex (VCNX) announced the signing of several proprietary project agreements with Amgen, Merck, Chugai, Absci, Gigagen, Merus, Soleil, ...

Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

Welcome to the Merck & Company Q3 sales and earnings conference call. [Operator instructions] This call is being recorded.

Are you a print subscriber? Activate your account. By Garett Sloane - 2 hours 35 min ago By Gillian Follett - 2 hours 35 min ago By E.J. Schultz - 2 hours 35 min ago By Jack Neff - 2 hours 35 min ...

We recently compiled a list of the 9 Best Dow Stocks to Buy According to Analysts. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other Dow ...

The CDC's updated guidelines aim to protect more elderly individuals, highlighting the effectiveness of the recently approved Capvaxive vaccine from Merck. The yearly invasive pneumococcal disease ...

Merck’s recently approved vaccine, however, gives Pfizer some major competition. The shot, called Capvaxive, protects against bacterial strains that cause about 84% of cases of adult ...

This year, pharmaceutical giant Merck (NYSE: MRK) is it: The drugmaker's shares are down by 2% in 2024 while the broader S&P 500 is up by 21%. Even when we zoom out, Merck hasn't performed ...

Developed by US pharma giant Merck & Co (NYSE: MRK), Capvaxive gained US Food and Drug Administration in June this year. The ACIP issued a similar recommendation for Pfizer’s (NYSE: PFE) Prevnar 20 ...

According to the Associated Press, there are four types of pneumococcal vaccine available to Americans, including Capvaxive, made by Merck, which can cost around $300 a dose and protects against ...

There are four vaccines now in use. The U.S. Food and Drug Administration this year approved the newest — Merck’s Capvaxive, which can cost around $300 a dose and protects against 21 types ...